US20220232822A1 - Solutions for increasing the stability and shelf life of an organ and tissue preservation solution - Google Patents
Solutions for increasing the stability and shelf life of an organ and tissue preservation solution Download PDFInfo
- Publication number
- US20220232822A1 US20220232822A1 US17/684,495 US202217684495A US2022232822A1 US 20220232822 A1 US20220232822 A1 US 20220232822A1 US 202217684495 A US202217684495 A US 202217684495A US 2022232822 A1 US2022232822 A1 US 2022232822A1
- Authority
- US
- United States
- Prior art keywords
- solution
- concentration
- organ
- tissue
- sugar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000243 solution Substances 0.000 title claims abstract description 170
- 210000000056 organ Anatomy 0.000 title claims abstract description 46
- 239000003761 preservation solution Substances 0.000 title claims abstract description 32
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 58
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 50
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 29
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 23
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 23
- 229930064664 L-arginine Natural products 0.000 claims abstract description 23
- 235000000346 sugar Nutrition 0.000 claims abstract description 23
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 20
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 20
- 239000003855 balanced salt solution Substances 0.000 claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 15
- 239000007864 aqueous solution Substances 0.000 claims abstract description 15
- 229910001868 water Inorganic materials 0.000 claims abstract description 11
- ZUKPVRWZDMRIEO-VKHMYHEASA-N L-cysteinylglycine Chemical compound SC[C@H]([NH3+])C(=O)NCC([O-])=O ZUKPVRWZDMRIEO-VKHMYHEASA-N 0.000 claims abstract description 7
- 108010016616 cysteinylglycine Proteins 0.000 claims abstract description 7
- 210000001519 tissue Anatomy 0.000 claims description 55
- 238000000034 method Methods 0.000 claims description 34
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 20
- 108010024636 Glutathione Proteins 0.000 claims description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 15
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 14
- 235000002639 sodium chloride Nutrition 0.000 claims description 12
- 229960003180 glutathione Drugs 0.000 claims description 10
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 10
- 210000003752 saphenous vein Anatomy 0.000 claims description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 8
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 claims description 7
- 229940052299 calcium chloride dihydrate Drugs 0.000 claims description 7
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 claims description 7
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 claims description 7
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 claims description 7
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 claims description 7
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 7
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 7
- 239000001103 potassium chloride Substances 0.000 claims description 7
- 235000011164 potassium chloride Nutrition 0.000 claims description 7
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 239000008103 glucose Substances 0.000 claims description 6
- 235000003969 glutathione Nutrition 0.000 claims description 6
- 210000002216 heart Anatomy 0.000 claims description 6
- PYLIXCKOHOHGKQ-UHFFFAOYSA-L disodium;hydrogen phosphate;heptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O PYLIXCKOHOHGKQ-UHFFFAOYSA-L 0.000 claims description 5
- 210000003734 kidney Anatomy 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 210000000988 bone and bone Anatomy 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 210000002815 epigastric artery Anatomy 0.000 claims description 3
- 210000004300 gastroepiploic artery Anatomy 0.000 claims description 3
- 210000000936 intestine Anatomy 0.000 claims description 3
- 210000003205 muscle Anatomy 0.000 claims description 3
- 210000002321 radial artery Anatomy 0.000 claims description 3
- 210000003491 skin Anatomy 0.000 claims description 3
- 239000002243 precursor Substances 0.000 claims 22
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 2
- 125000002353 D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- RWSXRVCMGQZWBV-PHDIDXHHSA-N L-Glutathione Natural products OC(=O)[C@H](N)CCC(=O)N[C@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-PHDIDXHHSA-N 0.000 abstract description 18
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract description 12
- 239000003638 chemical reducing agent Substances 0.000 abstract description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 28
- 230000002792 vascular Effects 0.000 description 23
- 239000000203 mixture Substances 0.000 description 17
- 229910052786 argon Inorganic materials 0.000 description 14
- 238000009472 formulation Methods 0.000 description 12
- 238000003860 storage Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 10
- 239000002211 L-ascorbic acid Substances 0.000 description 9
- 235000000069 L-ascorbic acid Nutrition 0.000 description 9
- 238000001356 surgical procedure Methods 0.000 description 7
- 230000004913 activation Effects 0.000 description 6
- 239000006172 buffering agent Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000004321 preservation Methods 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 238000013213 extrapolation Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 102000003951 Erythropoietin Human genes 0.000 description 4
- 108090000394 Erythropoietin Proteins 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 229940105423 erythropoietin Drugs 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 210000003038 endothelium Anatomy 0.000 description 3
- 239000000644 isotonic solution Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004792 oxidative damage Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 238000002690 local anesthesia Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000013618 particulate matter Substances 0.000 description 2
- 102220201076 rs201475876 Human genes 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- WXBGSMXDIABHSO-DBQHITQZSA-N 4-[(1r)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol;methyl 4-methyl-3-[2-(propylamino)propanoylamino]thiophene-2-carboxylate;dihydrochloride Chemical compound Cl.Cl.CNC[C@H](O)C1=CC=C(O)C(O)=C1.CCCNC(C)C(=O)NC=1C(C)=CSC=1C(=O)OC WXBGSMXDIABHSO-DBQHITQZSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 238000012371 Aseptic Filling Methods 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010051269 Graft thrombosis Diseases 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 206010060872 Transplant failure Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 229940114029 articaine / epinephrine Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002788 crimping Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000005429 filling process Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000007443 liposuction Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000000162 organ preservation solution Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 239000008229 sterile water for irrigation Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000004218 vascular function Effects 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
Definitions
- the present invention is directed to formulations for preserving tissue and organ function and more particularly to shelf stable formulations for preserving tissue and organ function, in particular the function of vascular conduits, prior to implantation.
- U.S. Pat. No. 7,981,596 discloses tissue and organ preservation solutions, generally called GALA. This is named after three components: glutathione, ascorbic acid and L-Arginine. GALA solutions also include a balanced salt solution. These solutions are especially useful for preserving vascular conduits such as arteries and veins.
- Vascular conduits are used as grafts for a variety of bypass surgical procedures including but not limited to peripheral vascular bypass surgery and coronary artery bypass grafting (CABG) surgery.
- Bypass grafting is a method in which a vascular conduit is grafted in such a way as to bypass an obstructed artery to restore blood flow to a target tissue.
- vascular conduits are harvested, flushed and stored temporarily in a preservation solution prior to their grafting.
- Endothelial dysfunction is the primary determinant in the interrelated pathogenesis leading to vascular conduit failure.
- Graft failure is preceded by graft thrombosis, intimal hyperplasia and accelerated graft atherosclerosis all of which are predicated upon previous functional and/structural impairment of the vascular conduit endothelium. It has been recognized that the choice of storage solution for intra-operatively harvested saphenous vein segments has a significant impact on endothelial structure and function and therefore graft patency. The inability of these solutions to adequately preserve the vascular conduit has been demonstrated by a number of investigators (Thatte H S, Biswas K S, Najjar S F, et al.
- GALATM preservation solution was evaluated in ex vivo studies. While solutions in clinical use today led to a profound decline in endothelial cell viability of vascular conduits (saphenous vein), GALATM maintained endothelial function and structural viability for at least up to 24 hours (Thatte 2003, Circulation 2013:127 e6-e245 Hussaini B E, Lu X G, Wolfe J A and Thatte S. Evaluation of endoscopic vein extraction on structural and functional viability of saphenous vein endothelium. J Cariothorac Surg 2011; 6:82-90). The ex vivo data thus demonstrated that better preservation of vascular conduits could be afforded through the use of GALATM as a vascular conduit preservation solution. However, the disclosed solution has a limited shelf life due to instability of the Solution.
- the present invention is premised on realization that stability the GALA formulation, can be improved by separating the formulation into a first Solution A having a pH of at least 7, generally 7.4-8 and a Solution B having a pH of less than 7, generally lower.
- Solution A includes a balanced salt solution.
- Solution B includes water, an antioxidant such as ascorbic acid, a reducing agent, in particular L-glutathione, a nitric oxide substrate such as L-Arginine and a sugar, such as D-glucose.
- This solution is maintained at a pH below 7, preferably 5, 4 or 3, and preferably with an oxygen content at zero parts per million.
- Solutions A and B are formulated as stated above, with the exception that the sugar is added to Solution A and not in Solution B.
- erythropoietin (EPO) can be added, preferably to Solution B.
- FIG. 1 is a perspective view of a multi-chamber bag for use in the present invention
- FIG. 2 is a perspective view of a kit having a first and a second container for use with the present invention
- FIGS. 3A and 3B are graphs representing the concentration over time at accelerated storage conditions of glutathione, ascorbic acid and Arginine;
- FIG. 4 are two graphs depicting the degradation rate of L-glutathione in Solution B.
- FIGS. 5A-5D are diagrammatic depictions of the method of practicing the present invention.
- patient includes members of the animal kingdom including but not limited to human beings.
- organ includes, but is not limited to, the heart, veins, arteries, lungs, liver, pancreas and the kidneys. Portions of organs are also contemplated.
- sterile water includes, but is not limited to, (a) sterile water for injection, USP, (b) sterile distilled deionized water, and (c) sterile water for irrigation.
- cardioplegia includes, but is not limited to, paralysis of the heart.
- Moderate hypothermia is about 10.degree.-21.degree. C.
- an “antioxidant” is a substance that, when present in a mixture or structure containing an oxidizable substrate biological molecule, delays or prevents oxidation of the substrate biological molecule.
- ascorbic acid is an antioxidant.
- “Balanced salt solution” is defined as an aqueous solution that is osmotically balanced to prevent acute cell or tissue damage.
- “Buffered salt solution” is defined as a balanced salt solution to which chemicals have been added to maintain a predetermined physiological pH range.
- GALA refers to a type of tissue preservation solution including glutathione, ascorbic acid, L-Arginine and a balanced salt solution.
- “Graft” is defined as tissue that is transplanted or implanted in a part of the body to repair a defect.
- Hard bypass conduit is defined as a surgically installed alternate route for the blood to bypass an obstruction.
- Solution of cardioplegia is defined as a solution that aids in the preservation of the heart during transport or surgery.
- Cellular reducing agent is defined as a substance that loses electrons easily thereby causing other substances to be reduced chemically.
- a “buffering agent” is an acid or base used to maintain the acidity (pH) of a solution near a chosen value.
- Preferred buffering agents used to produce the solutions of the present invention are 4N HCl and 84% NaHCO 3 .
- An isotonic solution refers to two solutions having the same osmotic pressure across a semipermeable membrane.
- An isotonic solution is a solution that has the same salt concentration as cells.
- Physiologic solution is defined as an aqueous salt solution which is compatible with normal tissue, by virtue of being isotonic with normal interstitial fluid.
- the present invention provides a GALA-type tissue preservation formulation comprised of two solutions, Solution A and Solution B having unexpectedly higher stability than prior single-solution tissue preservation solutions of the GALA type.
- the first solution, or Solution A is comprised of a balanced salt solution.
- the balanced salt solution is comprised of water and physiologically acceptable salts.
- a typical balanced salt solution will be comprised of water, calcium ions, chloride ions, potassium ions, phosphate ions, magnesium ions and sodium ions.
- the balanced salt solution includes salts selected from the following: calcium chloride dihydrate, potassium chloride, potassium phosphate monobasic, magnesium chloride hexahydrate, magnesium sulfate heptahydrate, sodium chloride, sodium bicarbonate, sodium phosphate dibasic heptahydrate and combinations thereof.
- the balanced salt solution is provided at a concentration that will result in an isotonic solution when the first and second solutions are mixed together.
- the balanced salt solution includes about 0.14 grams/liter calcium chloride dihydrate, about 0.4 grams/liter potassium chloride, 0.06 grams/liter potassium phosphate monobasic, about 0.1 grams/liter magnesium chloride hexahydrate, about 0.1 grams/liter magnesium sulfate heptahydrate, about 8 grams/liter sodium chloride, about 0.36 grams/liter sodium bicarbonate, and about 0.03 grams/liter sodium phosphate dibasic heptahydrate.
- Solution A The components of Solution A are dissolved together in water and the pH of the resultant solution is adjusted to about 7.4-8.0 by the addition of a base, such as sodium bicarbonate.
- a base such as sodium bicarbonate.
- Solution A can contain non-steroidal anti-inflammatory agents such as aspirin, naproxen and ibuprofen.
- local anesthesia medications may be added, preferably in Solution A or, in the alternative, the anesthesia medication can be added at the point of use. Examples of such local anesthesia medications include but are not limited to lidocaine, articaine/epinephrine, mepivacaine, bupivacaine, ropicavaine and chloroprocaine.
- the following components of GALA will be in a second solution, or Solution B: reduced Glutathione, a reducing agent such as ascorbic acid; a sugar such as D-Glucose, L-Arginine, a buffering agent, and water which has been purged with an inert gas, such as argon, to remove substantially all dissolved oxygen (preferably to less than 0.1 ppm).
- the pH of resultant Solution B is less than 7 and generally from 3 to 5.
- cysteinylglycine can be substituted for reduced Glutathione or a mixture of cysteinylglycine and reduced Glutathione can be present in Solution B.
- the pH of Solution A is 8.0 and the pH of Solution B is about 3.0.
- Solution B is a solution of organic components in a separate container from Solution A and comprised of L-glutathione, L-Arginine, L-ascorbic acid, D-glucose and H 2 O for injection at a pH of 3.0-5.0.
- Other sugars that can be used in place of glucose are any sugar but preferably any monosaccharide including but not limited to fructose, mannose and ribose.
- the pH of the mixed solution is 7.3 ⁇ 0.4.
- the pH of the Solutions A and B can be adjusted using many known buffering agents. Preferred buffering agents are 4N HCl and 84% NaHCO 3 .
- the pH of Solution A is about 7.8 and the pH of Solution B is about 4.0.
- the pH of Solution A is 8.0 and the pH of solution B is 3.0.
- the salts in the solution are intended for buffering (maintain pH) and to maintain isotonicity with respect to vascular conduits.
- the organic components are intended to maintain additional buffering capability, osmolality and to provide a non-oxidizing environment to vascular conduits.
- the four organic components; L-glutathione, L-ascorbic acid, L-Arginine and D-glucose, are normal constituents of blood and are included for their roles in preserving and maintaining the extracellular environment of vascular conduits.
- L-Glutathione and L-ascorbic acid are antioxidants that prevent oxidative damage to cells by soaking up free radicals.
- the function of these antioxidants in the tissue preservation solution is, 1) to stabilize other components of the solution by preventing oxidation, thereby improving the stability and shelf life of product and 2) to prevent oxidative damage to cell membranes and extracellular matrix structures. Oxidative damage has been shown to break the structural integrity of the extracellular architecture, thus causing interrupted endothelial cell lining. Interrupted endothelial lining is an indicator of damaged vascular graft.
- the sugar is intended to provide an energy source for the tissue or organ.
- the concentration of L-arginine should be from about 250 ⁇ M to about 2000 ⁇ M.
- the concentration of glucose should be about 50 mM to about 120 mM, L-glutathione 50 ⁇ M to about 2000 ⁇ M, and L-ascorbic acid 25 ⁇ M to about 1000 ⁇ M,
- the first or second formulations may optionally include an anticoagulant in an amount sufficient to help prevent clotting of blood within the vasculature of a tissue or organ.
- anticoagulants include heparin and hirudin, but other anticoagulants such as aspirin may be used.
- An exemplary embodiment includes heparin in concentration ranges from about 50 units/mL to about 250 units/mL. Heparin can also be added separately after Solutions A and B have been combined and prior to use.
- the volumetric ratio between Solution A and Solution B is about 19:1.
- 950 ml of Solution A is mixed with 50 ml of Solution B to result in the final formulation for preserving the function of a tissue or organ.
- the concentration of EPO should be about 5 units/mL when Solution A and Solution B are combined.
- a second alternative tissue preservation solution includes a solution A, which includes a sugar such as glucose, mannose, fructose or the like, in combination with a balanced salt solution at a pH of 7.4 to 8 and a second solution, Solution B, comprises reduced glutathione, ascorbic acid, L-Arginine, a buffering agent in water at a pH below 7, generally 5, 4 or 3, which may be stored in an oxygen-free environment.
- a solution A which includes a sugar such as glucose, mannose, fructose or the like
- a balanced salt solution at a pH of 7.4 to 8
- Solution B comprises reduced glutathione, ascorbic acid, L-Arginine, a buffering agent in water at a pH below 7, generally 5, 4 or 3, which may be stored in an oxygen-free environment.
- neither Solution A or B in either embodiment will include other organic components other than those specifically listed, as these would be unnecessary and increase production costs.
- organic compounds other than those previously listed which are found in other types of tissue preservation solutions would not be included in Solutions A or B, to minimize cost and reduce potential side reactions, which could be detrimental to the final product.
- the manufacturing process is robust, and is carried out under cGMP conditions.
- the product is sterilized by aseptic filling procedures and stability testing provides a proposed shelf life of at least 2 years.
- FIG. 1 and FIG. 2 show exemplary embodiments of kits or containers used to ship, store and finally use the tissue preservation solutions of the present invention. These are exemplary and other containers can be used to provide separate Solutions A and B which are combined at the point of use for tissue preservation.
- FIG. 1 shows a bag 10 having two chambers 12 and 14 that are partitioned or clamped off from each other by clamp 16 .
- Chamber 12 contains Solution A and chamber 14 contains Solution B.
- clamp 16 When clamp 16 is removed, chambers 12 and 14 become one chamber of bag 10 and Solution A mixes with Solution B resulting in the complete organ and tissue preservation solution in bag 10 . See U.S. Pat. No. 5,257,985.
- FIG. 2 shows an organ and tissue preservation kit 20 having two containers 22 and 24 .
- Solution A is contained in container 22
- Solution B is contained in container 24 .
- the contents of container 24 can be emptied into container 22 or the contents of both container 22 and container 24 can be both emptied into a basin or bowel into which an artery or vein can be placed to produce the complete organ and tissue preservation solution.
- Solution A is aseptically filled in a pre-sterilized Nalgene bottle, which is then secured with a pre-sterilized HDPE screw cap.
- Solution B is aseptically filled in a pre-sterilized borosilicate, Type I, glass vial, which is secured with a pre-sterilized Stelmi septum, which is held in place with a tear-off seal.
- the tear-off seal is crimped to the bottle using a validated crimping process at the manufacturer's recommended crimp setting.
- Bottle B may be de-gassed with Argon gas during the mixing and filling process to reduce the presence of oxygen but this may not be necessary.
- the bottle containing solution A and the bottle containing solution B are then placed in a card-stock preprinted box.
- the package insert is also placed in the box at this time.
- the box is then sealed and labeled for distribution.
- Solutions A & B are mixed together to complete the final Solution C of GALA and the pH will be adjusted to about 7.3 ⁇ 0.4. If the pH of Solution A is 8.0 the pH of Solution B will be about 3.0. If the pH of Solution A is 7.8 the pH of Solution B will be about 4.0. And, if the pH of Solution A is 7.6 the pH of Solution B will be about 5.0.
- the solution is used to flush the isolated vascular conduit 32 immediately after removal from the patient.
- the combined solutions A and B may also be used in combination with a syringe to apply a hydrostatic pressure to the conduit to assess for conduit leakage prior to storage in the solution.
- the vascular conduit 32 is then stored in the combined solution 34 in container 26 until the vascular conduit can be grafted into the patient.
- the solutions, devices, and perfusion methods of the present invention are not limited to use with a particular tissue, organ or cell type.
- the invention may be used with harvested saphenous veins, epigastric arteries, gastroepiploic arteries and radial arteries used in coronary bypass grafting (CABG).
- CABG coronary bypass grafting
- the present invention may also be used to maintain organs and tissue during transplant operations.
- the present invention is not limited to any particular tissue or organ.
- it is contemplated that such organs or tissues may be heart, lungs, kidney, brain, blood, platelets, muscle grafts, skin, intestine, bone, appendages, eyes, etc or portions thereof.
- the present invention may be used as an in situ tissue or organ preservative.
- the solution of the present invention be used to wash and bath tissues and organs that have not been removed from the patient.
- the present invention be used during cardioplegia.
- the present invention be used in, for example, emergency procedures where a tissue or organ may need to be bathed to preserve it until surgery or other medical attention can be obtained.
- the solution may be made available to emergency medical personnel both in hospital settings and “in the field” (i.e., in ambulances or in temporary emergency medical facilities).
- the GALA solution can also be used as a lavage-solution in surgeries, in particular plastic or reconstructive surgery. This includes but is not limited to liposuction, breast reconstruction, mastectomy or other operations in which an isotonic, pH-balanced solution such as GALA would be desirable.
- the GALA solution can also be used to flush or prime a dialysis machine using the manufacturer's procedure for priming or flushing.
- the GALA solution can also be used in conjunction with a venous external support.
- a venous external support An example of such a support is the VestTM vascular external support being developed by Vascular Graft Solutions of Tel-Aviv, Israel.
- the components of the organ and tissue preservation solutions can also be incorporated into gels, creams, or hydrogels.
- examples of hydrogels are disclosed in U.S. Pat. No. 6,339,074.
- Table 1 below shows an embodiment of the present invention in which the pH of the Solution A is about 8.0 and the pH of Solution B is about 3.0.
- Solution A and Solution B from Table 1 Multiple lots of Solution A and Solution B from Table 1 were produced. Twenty-one sets of Solution A and B containers from three separate lots were placed in a qualified stability chamber maintained at 40° C. with 75% relative humidity. Solution containers from each of the lots were periodically taken and tested under these accelerated conditions. The results of this data were extrapolated to determine the shelf life of the product, had it been stored at 2-8° C. Shelf life determination was based on assessment of the minimum duration of time that the product solutions remained within set specifications. The pH, osmolality and conductivity of the solutions A and B were studied. The eight inorganic salts that constitute Solution A are inert and remain stable in aqueous media for extended periods of time.
- the data obtained while storing the solution at 40° C. was extrapolated to the average 5° storage temperature of such solutions using a Q10 factor of 2. Based on this extrapolation, it is predicted that the storage stability of Solution B is about 900 days, providing a shelf life of at least two years, far exceeding the requirements in the industry and far exceeding the stability of the current formulations.
- the raw data obtained showing concentration of glutathione is shown in FIG. 3A and the concentration over time for ascorbic acid and Arginine are shown in FIG. 3B .
- k1 and k2 are the rate constants at temperatures T1 and T2 with shelf lives SL1 and SL2.
- the value of the temperature coefficient Q10 is dependent on the energy of activation Ea for the reaction. Therefore Q10 may be calculated using the above equation if the rate constants are known for at least two different temperatures. Values of Q10 are typically 2, 3, or 4 depending on whether the desired estimates of shelf lives are a) conservative, b) probable and reasonable, or c) less conservative but possible, respectively. As a rule of thumb a Q10 of 2 corresponds to Ea of 12.2 kcal/mol, 3 for 19.4 kcal/mol, and 4 for 24.5 kcal/mol.
- the first order rate constant for the decomposition of L-glutathione in Solution B at 40° C. was determined to be 0.0643 days' from accelerated studies of two Lots of Solution B— one with Argon in the headspace and the other without. These profiles are shown together in FIG. 4 .
- the first order exponential decay is shown in the lower plot, and the corresponding linear logarithmic plot is shown in the top plot.
- the product specification for L-glutathione approached its limit of expiration in approximately 73 days.
- This empirically derived value of 2.94 for the temperature coefficient Q10 is higher than the value of 2 used in previous calculations of shelf life.
- the shelf life of Solution B can be recalculated by either extrapolating the 40° C. shelf life data and/or directly from the exponential fit of the one-year real time data at 5° C.
- the revised values are tabulated in Table 3.
- shelf life is significantly improved by separating the components of the GALA solution into a higher pH balanced salt solution, which optionally may include glucose, and storing the organic components, particularly the L-arginine ascorbic acid and glutathione plus optionally a sugar at much lower pH. It has been unexpectedly discovered that increasing the stability of reduced glutathione also increases the stability of ascorbic acid and L-Arginine. The storage stability of the two solutions far exceeds commercial expectations or needs, making this formulation much more practical and suitable for a wide variety of different environments. This provides an end result of improved graft performance, improving cell viability of the graft material.
Abstract
Organ and tissue preservation solutions having improved stability are disclosed. The solutions are comprised of two separate solutions. The first solution, Solution A, is comprised of a balanced salt solution that is stable in solution at a pH of 7.0 or above. A second solution, Solution B, is comprised of an aqueous solution containing L-glutathione and/or cysteinylglycine, a sugar such as D-glucose, L-Arginine, a reducing agent such as ascorbic acid and water at a pH of below 7.0, preferably from about 3.0 to 5.0. The two Solutions are then mixed together at the point of use and the pH adjusted to about 7.3 resulting in the organ and tissue preservation solution having improved stability. Preferably, solution A has a pH of about 7.6 and solution B has a pH of about 5.0. The present invention is also comprised of kits 20 that contain the two Solutions in two separate containers 22, 24. In an alternate embodiment, the sugar can be in Solution A.
Description
- This application claims the benefit of and priority to prior filed pending U.S. Provisional Patent Application Ser. No. 61/963,093 filed Nov. 22, 2013, the disclosure of which is hereby incorporated herein by reference in its entirety.
- The present invention is directed to formulations for preserving tissue and organ function and more particularly to shelf stable formulations for preserving tissue and organ function, in particular the function of vascular conduits, prior to implantation.
- The teachings of all the references cited herein are incorporated in their entirety by reference.
- U.S. Pat. No. 7,981,596 discloses tissue and organ preservation solutions, generally called GALA. This is named after three components: glutathione, ascorbic acid and L-Arginine. GALA solutions also include a balanced salt solution. These solutions are especially useful for preserving vascular conduits such as arteries and veins. Vascular conduits are used as grafts for a variety of bypass surgical procedures including but not limited to peripheral vascular bypass surgery and coronary artery bypass grafting (CABG) surgery. Bypass grafting is a method in which a vascular conduit is grafted in such a way as to bypass an obstructed artery to restore blood flow to a target tissue. During vascular surgeries, vascular conduits are harvested, flushed and stored temporarily in a preservation solution prior to their grafting.
- Endothelial dysfunction is the primary determinant in the interrelated pathogenesis leading to vascular conduit failure. Graft failure is preceded by graft thrombosis, intimal hyperplasia and accelerated graft atherosclerosis all of which are predicated upon previous functional and/structural impairment of the vascular conduit endothelium. It has been recognized that the choice of storage solution for intra-operatively harvested saphenous vein segments has a significant impact on endothelial structure and function and therefore graft patency. The inability of these solutions to adequately preserve the vascular conduit has been demonstrated by a number of investigators (Thatte H S, Biswas K S, Najjar S F, et al. Multi-photon microscopic evaluation of saphenous vein endothelium and its preservation with a new solution, GALA. Ann Thorac Surg 2003; 75: 1145-52 and Hussaini 2011). In a 2011 ex vivo study by Wilbring et al demonstrated that vascular function was completely abolished after conduits harvested from patients were stored in a buffered saline solution, commonly used for vascular conduit storage. The data revealed that endothelial cell function was also significantly reduced yet these dysfunctional conduits were successfully used as grafts for bypass surgery in this study.
- The effect of GALA™ preservation solution on human saphenous vein segments was evaluated in ex vivo studies. While solutions in clinical use today led to a profound decline in endothelial cell viability of vascular conduits (saphenous vein), GALA™ maintained endothelial function and structural viability for at least up to 24 hours (Thatte 2003, Circulation 2013:127 e6-e245 Hussaini B E, Lu X G, Wolfe J A and Thatte S. Evaluation of endoscopic vein extraction on structural and functional viability of saphenous vein endothelium. J Cariothorac Surg 2011; 6:82-90). The ex vivo data thus demonstrated that better preservation of vascular conduits could be afforded through the use of GALA™ as a vascular conduit preservation solution. However, the disclosed solution has a limited shelf life due to instability of the Solution.
- Thus, there is a need to produce improved Solutions of the GALA organ and tissue preservation solutions to improve the stability and shelf life of the Solution.
- The present invention is premised on realization that stability the GALA formulation, can be improved by separating the formulation into a first Solution A having a pH of at least 7, generally 7.4-8 and a Solution B having a pH of less than 7, generally lower. Solution A includes a balanced salt solution. Solution B includes water, an antioxidant such as ascorbic acid, a reducing agent, in particular L-glutathione, a nitric oxide substrate such as L-Arginine and a sugar, such as D-glucose. This solution is maintained at a pH below 7, preferably 5, 4 or 3, and preferably with an oxygen content at zero parts per million. In an alternate embodiment of the present invention, Solutions A and B are formulated as stated above, with the exception that the sugar is added to Solution A and not in Solution B. Also, in an alternative formulation erythropoietin (EPO) can be added, preferably to Solution B.
-
FIG. 1 is a perspective view of a multi-chamber bag for use in the present invention; -
FIG. 2 is a perspective view of a kit having a first and a second container for use with the present invention; -
FIGS. 3A and 3B are graphs representing the concentration over time at accelerated storage conditions of glutathione, ascorbic acid and Arginine; -
FIG. 4 are two graphs depicting the degradation rate of L-glutathione in Solution B; and -
FIGS. 5A-5D are diagrammatic depictions of the method of practicing the present invention. - Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are described. For purposes of the present invention, the following terms are defined below.
- As used herein, the term “patient” includes members of the animal kingdom including but not limited to human beings.
- As employed herein, “organ” includes, but is not limited to, the heart, veins, arteries, lungs, liver, pancreas and the kidneys. Portions of organs are also contemplated.
- As used herein, “sterile water” includes, but is not limited to, (a) sterile water for injection, USP, (b) sterile distilled deionized water, and (c) sterile water for irrigation.
- As used herein, “cardioplegia” includes, but is not limited to, paralysis of the heart.
- As used herein, “moderate hypothermia” is about 10.degree.-21.degree. C.
- As used herein, an “antioxidant” is a substance that, when present in a mixture or structure containing an oxidizable substrate biological molecule, delays or prevents oxidation of the substrate biological molecule. For example, ascorbic acid is an antioxidant.
- “Balanced salt solution” is defined as an aqueous solution that is osmotically balanced to prevent acute cell or tissue damage.
- “Buffered salt solution” is defined as a balanced salt solution to which chemicals have been added to maintain a predetermined physiological pH range.
- “GALA” refers to a type of tissue preservation solution including glutathione, ascorbic acid, L-Arginine and a balanced salt solution.
- “Graft” is defined as tissue that is transplanted or implanted in a part of the body to repair a defect.
- “Harvested bypass conduit” is defined as a surgically installed alternate route for the blood to bypass an obstruction.
- “Solution of cardioplegia” is defined as a solution that aids in the preservation of the heart during transport or surgery.
- “Cellular reducing agent” is defined as a substance that loses electrons easily thereby causing other substances to be reduced chemically.
- A “buffering agent” is an acid or base used to maintain the acidity (pH) of a solution near a chosen value. Preferred buffering agents used to produce the solutions of the present invention are 4N HCl and 84% NaHCO3.
- An isotonic solution refers to two solutions having the same osmotic pressure across a semipermeable membrane. An isotonic solution is a solution that has the same salt concentration as cells.
- Physiologic solution is defined as an aqueous salt solution which is compatible with normal tissue, by virtue of being isotonic with normal interstitial fluid.
- The present invention provides a GALA-type tissue preservation formulation comprised of two solutions, Solution A and Solution B having unexpectedly higher stability than prior single-solution tissue preservation solutions of the GALA type.
- According to the present invention, the first solution, or Solution A is comprised of a balanced salt solution. The balanced salt solution is comprised of water and physiologically acceptable salts. A typical balanced salt solution will be comprised of water, calcium ions, chloride ions, potassium ions, phosphate ions, magnesium ions and sodium ions.
- The balanced salt solution includes salts selected from the following: calcium chloride dihydrate, potassium chloride, potassium phosphate monobasic, magnesium chloride hexahydrate, magnesium sulfate heptahydrate, sodium chloride, sodium bicarbonate, sodium phosphate dibasic heptahydrate and combinations thereof. The balanced salt solution is provided at a concentration that will result in an isotonic solution when the first and second solutions are mixed together. In an exemplary embodiment, the balanced salt solution includes about 0.14 grams/liter calcium chloride dihydrate, about 0.4 grams/liter potassium chloride, 0.06 grams/liter potassium phosphate monobasic, about 0.1 grams/liter magnesium chloride hexahydrate, about 0.1 grams/liter magnesium sulfate heptahydrate, about 8 grams/liter sodium chloride, about 0.36 grams/liter sodium bicarbonate, and about 0.03 grams/liter sodium phosphate dibasic heptahydrate.
- The components of Solution A are dissolved together in water and the pH of the resultant solution is adjusted to about 7.4-8.0 by the addition of a base, such as sodium bicarbonate.
- Optionally, Solution A can contain non-steroidal anti-inflammatory agents such as aspirin, naproxen and ibuprofen. Optionally, local anesthesia medications may be added, preferably in Solution A or, in the alternative, the anesthesia medication can be added at the point of use. Examples of such local anesthesia medications include but are not limited to lidocaine, articaine/epinephrine, mepivacaine, bupivacaine, ropicavaine and chloroprocaine.
- According to the present invention, the following components of GALA will be in a second solution, or Solution B: reduced Glutathione, a reducing agent such as ascorbic acid; a sugar such as D-Glucose, L-Arginine, a buffering agent, and water which has been purged with an inert gas, such as argon, to remove substantially all dissolved oxygen (preferably to less than 0.1 ppm). The pH of resultant Solution B is less than 7 and generally from 3 to 5. As an alternative, cysteinylglycine can be substituted for reduced Glutathione or a mixture of cysteinylglycine and reduced Glutathione can be present in Solution B. In a most preferred formulation, the pH of Solution A is 8.0 and the pH of Solution B is about 3.0.
- More specifically, Solution B is a solution of organic components in a separate container from Solution A and comprised of L-glutathione, L-Arginine, L-ascorbic acid, D-glucose and H2O for injection at a pH of 3.0-5.0. Other sugars that can be used in place of glucose are any sugar but preferably any monosaccharide including but not limited to fructose, mannose and ribose. When Solutions A and B are mixed at the point of use, the pH of the mixed solution is 7.3±0.4. The pH of the Solutions A and B can be adjusted using many known buffering agents. Preferred buffering agents are 4N HCl and 84% NaHCO3. In a preferred formulation, the pH of Solution A is about 7.8 and the pH of Solution B is about 4.0. In a most preferred formulation, the pH of Solution A is 8.0 and the pH of solution B is 3.0.
- The salts in the solution are intended for buffering (maintain pH) and to maintain isotonicity with respect to vascular conduits. The organic components are intended to maintain additional buffering capability, osmolality and to provide a non-oxidizing environment to vascular conduits. The four organic components; L-glutathione, L-ascorbic acid, L-Arginine and D-glucose, are normal constituents of blood and are included for their roles in preserving and maintaining the extracellular environment of vascular conduits.
- L-Glutathione and L-ascorbic acid are antioxidants that prevent oxidative damage to cells by soaking up free radicals. The function of these antioxidants in the tissue preservation solution is, 1) to stabilize other components of the solution by preventing oxidation, thereby improving the stability and shelf life of product and 2) to prevent oxidative damage to cell membranes and extracellular matrix structures. Oxidative damage has been shown to break the structural integrity of the extracellular architecture, thus causing interrupted endothelial cell lining. Interrupted endothelial lining is an indicator of damaged vascular graft. The sugar is intended to provide an energy source for the tissue or organ.
- When Solution A is combined with Solution B, the concentration of L-arginine should be from about 250 μM to about 2000 μM. The concentration of glucose should be about 50 mM to about 120 mM, L-
glutathione 50 μM to about 2000 μM, and L-ascorbic acid 25 μM to about 1000 μM, - The first or second formulations may optionally include an anticoagulant in an amount sufficient to help prevent clotting of blood within the vasculature of a tissue or organ. Exemplary anticoagulants include heparin and hirudin, but other anticoagulants such as aspirin may be used. An exemplary embodiment includes heparin in concentration ranges from about 50 units/mL to about 250 units/mL. Heparin can also be added separately after Solutions A and B have been combined and prior to use.
- In an exemplary embodiment, the volumetric ratio between Solution A and Solution B is about 19:1. For example in one embodiment, 950 ml of Solution A is mixed with 50 ml of Solution B to result in the final formulation for preserving the function of a tissue or organ.
- If EPO is added to either Solution A or B, the concentration of EPO should be about 5 units/mL when Solution A and Solution B are combined.
- According to the present invention, a second alternative tissue preservation solution includes a solution A, which includes a sugar such as glucose, mannose, fructose or the like, in combination with a balanced salt solution at a pH of 7.4 to 8 and a second solution, Solution B, comprises reduced glutathione, ascorbic acid, L-Arginine, a buffering agent in water at a pH below 7, generally 5, 4 or 3, which may be stored in an oxygen-free environment.
- Generally, neither Solution A or B in either embodiment will include other organic components other than those specifically listed, as these would be unnecessary and increase production costs. In particular, organic compounds other than those previously listed which are found in other types of tissue preservation solutions, would not be included in Solutions A or B, to minimize cost and reduce potential side reactions, which could be detrimental to the final product.
- The manufacturing process is robust, and is carried out under cGMP conditions. The product is sterilized by aseptic filling procedures and stability testing provides a proposed shelf life of at least 2 years.
-
FIG. 1 andFIG. 2 show exemplary embodiments of kits or containers used to ship, store and finally use the tissue preservation solutions of the present invention. These are exemplary and other containers can be used to provide separate Solutions A and B which are combined at the point of use for tissue preservation. -
FIG. 1 shows abag 10 having twochambers 12 and 14 that are partitioned or clamped off from each other byclamp 16.Chamber 12 contains Solution A and chamber 14 contains Solution B. Whenclamp 16 is removed,chambers 12 and 14 become one chamber ofbag 10 and Solution A mixes with Solution B resulting in the complete organ and tissue preservation solution inbag 10. See U.S. Pat. No. 5,257,985. -
FIG. 2 shows an organ andtissue preservation kit 20 having twocontainers container 22 and Solution B is contained incontainer 24. At the point of use, the contents ofcontainer 24 can be emptied intocontainer 22 or the contents of bothcontainer 22 andcontainer 24 can be both emptied into a basin or bowel into which an artery or vein can be placed to produce the complete organ and tissue preservation solution. - In a preferred embodiment as shown in
FIG. 2 , Solution A is aseptically filled in a pre-sterilized Nalgene bottle, which is then secured with a pre-sterilized HDPE screw cap. - Solution B is aseptically filled in a pre-sterilized borosilicate, Type I, glass vial, which is secured with a pre-sterilized Stelmi septum, which is held in place with a tear-off seal. The tear-off seal is crimped to the bottle using a validated crimping process at the manufacturer's recommended crimp setting. Bottle B may be de-gassed with Argon gas during the mixing and filling process to reduce the presence of oxygen but this may not be necessary.
- The bottle containing solution A and the bottle containing solution B are then placed in a card-stock preprinted box. The package insert is also placed in the box at this time. The box is then sealed and labeled for distribution.
- At the point of use Solutions A & B are mixed together to complete the final Solution C of GALA and the pH will be adjusted to about 7.3±0.4. If the pH of Solution A is 8.0 the pH of Solution B will be about 3.0. If the pH of Solution A is 7.8 the pH of Solution B will be about 4.0. And, if the pH of Solution A is 7.6 the pH of Solution B will be about 5.0.
- The following is a recommended procedure for practicing the present invention.
- Allow the
solutions container - 1. Pour the entire content of Solution A from
vial 22 into a sterile container 26 (e.g. tray, cup or small basin) where thevascular conduit 32 will be stored prior to grafting, as shown inFIG. 5A . - 2. With a
sterile syringe 28 aseptically remove 12.5 ml of Solution B fromvial 24 and add it to thecontainer 26 with solution A (FIG. 5B ) to form theGALA solution 34. - 3. Add 12,500 units of heparin to the
container 26 containing Solutions A and B as shown inFIG. 5C . - 4. Mix by gently swirling in the
container 26. - The solution is used to flush the isolated
vascular conduit 32 immediately after removal from the patient. The combined solutions A and B may also be used in combination with a syringe to apply a hydrostatic pressure to the conduit to assess for conduit leakage prior to storage in the solution. Thevascular conduit 32 is then stored in the combinedsolution 34 incontainer 26 until the vascular conduit can be grafted into the patient. - The solutions, devices, and perfusion methods of the present invention are not limited to use with a particular tissue, organ or cell type. For example, the invention may be used with harvested saphenous veins, epigastric arteries, gastroepiploic arteries and radial arteries used in coronary bypass grafting (CABG). The present invention may also be used to maintain organs and tissue during transplant operations. The present invention is not limited to any particular tissue or organ. For example, it is contemplated that such organs or tissues may be heart, lungs, kidney, brain, blood, platelets, muscle grafts, skin, intestine, bone, appendages, eyes, etc or portions thereof. Additionally, the present invention may be used as an in situ tissue or organ preservative. It is contemplated that the solution of the present invention be used to wash and bath tissues and organs that have not been removed from the patient. For example, it is contemplated that the present invention be used during cardioplegia. It is also contemplated that the present invention be used in, for example, emergency procedures where a tissue or organ may need to be bathed to preserve it until surgery or other medical attention can be obtained. In this regard, the solution may be made available to emergency medical personnel both in hospital settings and “in the field” (i.e., in ambulances or in temporary emergency medical facilities).
- The GALA solution (Solutions A and B combined) can also be used as a lavage-solution in surgeries, in particular plastic or reconstructive surgery. This includes but is not limited to liposuction, breast reconstruction, mastectomy or other operations in which an isotonic, pH-balanced solution such as GALA would be desirable. The GALA solution can also be used to flush or prime a dialysis machine using the manufacturer's procedure for priming or flushing. The GALA solution can also be used in conjunction with a venous external support. An example of such a support is the Vest™ vascular external support being developed by Vascular Graft Solutions of Tel-Aviv, Israel.
- The components of the organ and tissue preservation solutions can also be incorporated into gels, creams, or hydrogels. Examples of hydrogels are disclosed in U.S. Pat. No. 6,339,074.
- Table 1 below shows an embodiment of the present invention in which the pH of the Solution A is about 8.0 and the pH of Solution B is about 3.0.
-
TABLE 1 Qualitative & Quantitative Composition of Solutions A and B of One Embodiment Components *Concentration (±5%) SOLUTION A g/L g/237.5 mL mM Calcium chloride dihydrate 0.147 0.035 1.326 Potassium chloride 0.421 0.100 5.653 Potassium phosphate monobasic 0.063 0.015 0.463 Magnesium sulfate heptahydrate 0.105 0.025 0.432 Magnesium chloride hexahydrate 0.105 0.025 0.516 Sodium chloride 8.421 2.000 144.100 Sodium bicarbonate 0.379 0.090 4.390 Sodium phosphate dibasic anhydrous 0.028 0.007 0.200 Water for injection q.s. to q.s. to — 1 L 237.5 mL Sodium bicarbonate 1.0M/HCl 1.0M Adjust pH to 8.0 Components *Concentration (±5%) SOLUTION B g/L g/12.5 mL mM L-Glutathione 6.200 0.078 20.200 D-Glucose 20.000 0.25 111.000 L-Arginine 3.000 0.038 17.200 L-Ascorbic acid 1.800 0.023 10.200 Water for injection q.s. to q.s. to — 1 L 12.5 mL Sodium bicarbonate 1.0M/HCl 1.0M Adjust pH to 3.0 -
- The components of combined Solution A and Solution B are shown in Table 2:
-
TABLE 2 Qualitative and Quantitative Composition of the combined Solutions A & B Components *Concentration (±5%) SOLUTIONS A + B g/L g/250 mL mM Calcium chloride dihydrate 0.14 0.0348 1.26 Potassium chloride 0.40 0.0998 5.37 Potassium phosphate monobasic 0.06 0.0148 0.44 Magnesium sulfate heptahydrate 0.10 0.0248 0.41 Magnesium chloride hexahydrate 0.10 0.0248 0.49 Sodium chloride 8.00 1.9998 136.89 Sodium bicarbonate 0.36 0.0900 4.17 Sodium phosphate dibasic anhydrous 0.026 0.0065 0.187 L-Glutathione 0.31 0.0775 1.01 D-Glucose 1.00 0.2500 5.55 L-Arginine 0.15 0.0375 0.86 L-Ascorbic acid 0.09 0.0225 0.51 pH range after mixing A and B 7.3 ± 0.4 -
- The following examples are meant to illustrate the invention, but not limit it in any way.
- Multiple lots of Solution A and Solution B from Table 1 were produced. Twenty-one sets of Solution A and B containers from three separate lots were placed in a qualified stability chamber maintained at 40° C. with 75% relative humidity. Solution containers from each of the lots were periodically taken and tested under these accelerated conditions. The results of this data were extrapolated to determine the shelf life of the product, had it been stored at 2-8° C. Shelf life determination was based on assessment of the minimum duration of time that the product solutions remained within set specifications. The pH, osmolality and conductivity of the solutions A and B were studied. The eight inorganic salts that constitute Solution A are inert and remain stable in aqueous media for extended periods of time.
- Two of the components of solution B, L-Arginine and D-glucose, were also found to be stable for extended periods of time at pH of 3. Therefore with all of the remaining specifications meeting the acceptance criteria, the two components that influenced the final outcome of the shelf life of the product were L-ascorbic acid and L-glutathione due to their antioxidant properties.
- The rationale for the overall stability limiting property was for the solution to maintain conditions necessary for an overall reducing environment. When the solutions ceased to offer this benefit, it would fall out of specification. A reducing environment was achieved as long as some reduced L-glutathione and L-ascorbic acid, however small, remained in their reduced states in redox, equilibrium and solution. In other words, as long as L-glutathione and L-ascorbic acid each remained above detectable limits of the analytical method.
- The data obtained while storing the solution at 40° C. was extrapolated to the average 5° storage temperature of such solutions using a Q10 factor of 2. Based on this extrapolation, it is predicted that the storage stability of Solution B is about 900 days, providing a shelf life of at least two years, far exceeding the requirements in the industry and far exceeding the stability of the current formulations. The raw data obtained showing concentration of glutathione is shown in
FIG. 3A and the concentration over time for ascorbic acid and Arginine are shown inFIG. 3B . - According to the Q10 Rule, the relationships between rate constant, temperature, and shelf life may be expressed as:
-
- Where k1 and k2 are the rate constants at temperatures T1 and T2 with shelf lives SL1 and SL2. The value of the temperature coefficient Q10, is dependent on the energy of activation Ea for the reaction. Therefore Q10 may be calculated using the above equation if the rate constants are known for at least two different temperatures. Values of Q10 are typically 2, 3, or 4 depending on whether the desired estimates of shelf lives are a) conservative, b) probable and reasonable, or c) less conservative but possible, respectively. As a rule of thumb a Q10 of 2 corresponds to Ea of 12.2 kcal/mol, 3 for 19.4 kcal/mol, and 4 for 24.5 kcal/mol.
- During the early stages of regulatory submission of the product, when a detailed temperature-dependent kinetic data may not yet be available, a conservative estimate of shelf life must be made. A low activation energy for the degradation reaction is therefore assumed with a Q10 value of 2 for determining a conservative estimate of the product shelf life. According to this Rule the reaction rate would roughly double for every 10 degree rise in storage temperatures assuming a “most probable activation energy” for the reaction.
- The first order rate constant for the decomposition of L-glutathione in Solution B at 40° C. was determined to be 0.0643 days' from accelerated studies of two Lots of Solution B— one with Argon in the headspace and the other without. These profiles are shown together in
FIG. 4 . The first order exponential decay is shown in the lower plot, and the corresponding linear logarithmic plot is shown in the top plot. In addition, at this temperature (40° C.) the product specification for L-glutathione approached its limit of expiration in approximately 73 days. Using the arguments in the equation above, a conservative estimate of the shelf life at 5° C. storage can be estimated by extrapolation using a Q10 value of 2 as follows: -
- From this calculation therefore it can be inferred that at the very minimum the shelf life of Solution B would be predicted to be 27 months when the product is stored at 5° C.
- Detailed real time studies on the stability of three GMP Lots of Solution B at 2-8° C. after fifteen months of data collected, however, suggests that the 27-month shelf life estimate from accelerated studies might be extremely conservative and the actual Q10 factor is 2.94.
- The real time stability studies at 5° C. have progressed for about one year thus far. The available 12-15 month kinetic data of L-glutathione degradation from these Lots may be fitted to a first order reaction kinetics with a rate constant of about 1.40×103 days−1. At these rates, the product specification for L-glutathione approached its limit of expiration in about 100 months. Surprisingly, the shelf life determined on the basis of the 40° C. accelerated studies using Q10 extrapolation technique was significantly shorter (27 months) than what is suggested by the actual real time data. This discrepancy may be rationalized on the basis of the assumptions made during the Q10 extrapolation as described below.
- The observed rates for the degradation of L-glutathione in Solution B of Solution B under accelerated conditions of 40° C./75% RH over a 65-day period is shown in
FIG. 4 . Similar trends have been observed for several other Lots of Solution B. In all instances the rate of this reaction is purely exponential in character (first order) implying that equal elapsed time gives equal fractional decrease in analyte concentration, in this case the concentration of L-glutathione, over the time range studied. The rate constants at both 40° C. and 5° C. of all eleven Lots studied are summarized in Table 3. The values of the exponents in the equation derived from the exponential fit are the first order rate constant k1 (in units of days−1). These values are also presented in Table 3 at each of the temperatures studied. - This empirically derived value of 2.94 for the temperature coefficient Q10 is higher than the value of 2 used in previous calculations of shelf life. A value of Q10=2 represents a very conservative estimation of the shelf life resulting from a relatively low energy of activation of 12 kcal/mmol. A higher activation energy of 19 kcal/mmol with a value of Q10=2.94 on the other hand means that the reaction rate would roughly triple for every 10 degree rise in storage temperature with a corresponding inverse relationship to the shelf life.
- With the revised Q10 value of 2.94 which is more representative of the true energy of activation of 19.0 kcal/mol for L-glutathione decomposition, the shelf life of Solution B can be recalculated by either extrapolating the 40° C. shelf life data and/or directly from the exponential fit of the one-year real time data at 5° C. The revised values are tabulated in Table 3.
- The disparity in the results derived by the two approaches is illustrated in the comparison of the shelf lives at various temperatures between 5° C. and 60° C. by extrapolation the 40° C. empirical data using Q10 values 2 (conservative) and 2.94 (empirical). The results are shown in Table 4.
-
TABLE 3 Rate Constants & Shelf Life from Stability Studies Shelf Life, days Solution B [GSH] at at # head space g/L k1, days−1 Temperature ° C. 5° C.* 20 C.* Actual** 1 w/Argon 6.2 0.00143 5 3220 639 3220 2 w/Argon 6.4 0.00143 5 3220 639 3220 3 w/Argon 6.4 0.00140 5 3290 653 3290 4 wo/Argon 6.2 0.05937 40 3390 631 73 5 wo/Argon 6.2 0.06465 40 3100 622 72 6 wo/Argon 6.2 0.06465 40 3100 622 72 7 w/Argon 6.2 0.06378 40 3130 622 72 8 w/Argon 6.2 0.06465 40 3100 622 72 9 w/Argon 6.2 0.06465 40 3100 631 73 10 w/Argon 6.2 0.05780 40 3400 691 80 11 w/Argon 6.2 0.05608 40 3400 709 82 *extrapolated 40° C. to 5° C. and 20 C. using Q10 Rule with a Q10 value of 2.94 **Actual accelerated and real time data curve approaching 1% [GSH] -
TABLE 4 Extrapolated shelf lives of Solution B based on the old (conservative)and the new (empirical) Q10 values Storage Extrapolated Shelf Life, Days Temperature, ° C. Q10 = 2 Q10 = 2.94 5 830 3300 20 290 640 25 200 367 40 73 73 50 35 23 60 18 7 - Thus, shelf life is significantly improved by separating the components of the GALA solution into a higher pH balanced salt solution, which optionally may include glucose, and storing the organic components, particularly the L-arginine ascorbic acid and glutathione plus optionally a sugar at much lower pH. It has been unexpectedly discovered that increasing the stability of reduced glutathione also increases the stability of ascorbic acid and L-Arginine. The storage stability of the two solutions far exceeds commercial expectations or needs, making this formulation much more practical and suitable for a wide variety of different environments. This provides an end result of improved graft performance, improving cell viability of the graft material.
- This has been a description the present invention along with the preferred method of practicing present invention. However, the invention itself should only be defined by the appended claims.
Claims (23)
1-30. (canceled)
31. A method for preparing an organ or tissue preservation solution, comprising:
preparing a first precursor aqueous solution comprising a balanced salt solution, and having a pH of about 7.4 to 8.0, wherein the first precursor aqueous solution does not include L-Arginine, reduced glutathione, or ascorbic acid;
preparing a second precursor solution comprising water, sugar, L-Arginine, reduced glutathione, ascorbic acid and, optionally, cysteinylglycine, and having a pH of about 3.0 to 4.0; and
mixing the first precursor aqueous solution together with the second precursor solution at a point of use to form the organ and tissue preservation solution,
wherein the organ and tissue preservation solution has a pH of about 7.3.
32. A method for preserving a tissue or organ, comprising:
preparing the organ and tissue preservation solution according to claim 31 ; and
bringing a tissue or organ into contact with the organ and tissue preservation solution.
33. The method of claim 32 , wherein the tissue or organ is selected from the group consisting of saphenous veins, epigastric arteries, gastroepiploic arteries, radial arteries, heart, lungs, kidney, brain, muscle grafts, skin, intestine, bone, appendages, eyes, and portions of the tissue or organs.
34. The method of claim 31 , wherein the sugar is D-Glucose.
35. The method of claim 31 , wherein the second precursor solution comprises cysteinylglycine.
36. The method of claim 31 , wherein the balanced salt solution comprises:
calcium chloride dihydrate in a concentration of about 0.14 g/L;
potassium chloride in a concentration of about 0.4 g/L;
potassium phosphate monobasic in a concentration of about 0.06 g/L;
magnesium chloride hexahydrate in a concentration of about 0.1 g/L;
magnesium sulfate heptahydrate in a concentration of about 0.1 g/L sodium chloride in a concentration of about 8 g/L;
sodium bicarbonate in a concentration of about 0.36 g/L; and
sodium phosphate dibasic heptahydrate in a concentration of about 0.03 g/L.
37. The method of claim 31 , wherein the organ and tissue preservation solution comprises the ascorbic acid in a concentration of about 25-1000 μM, the glutathione in a concentration of about 50-2000 μM, the L-arginine in a concentration of about 250-2000 μM, and the sugar in a concentration of about 5.55 mM.
38. A method for preparing an organ or tissue preservation solution, comprising:
preparing a first precursor aqueous solution comprising a balanced salt solution, and having a pH of about 7.4 to 8.0, wherein the first precursor aqueous solution does not include L-Arginine, reduced glutathione, or ascorbic acid;
preparing a second precursor solution comprising water, L-Arginine, ascorbic acid, and reduced glutathione, and having a pH of about 3.0 to 4.0; and
mixing the first precursor aqueous solution together with the second precursor solution at a point of use to form the organ and tissue preservation solution,
wherein the organ and tissue preservation solution has a pH of about 7.3, and
wherein one of the first and second precursor aqueous solutions includes a sugar.
39. A method for preserving a tissue or organ, comprising:
preparing the organ and tissue preservation solution according to claim 38 ; and
bringing a tissue or organ into contact with the organ and tissue preservation solution.
40. The method of claim 39 , wherein the tissue or organ is selected from the group consisting of saphenous veins, epigastric arteries, gastroepiploic arteries, radial arteries, heart, lungs, kidney, brain, muscle grafts, skin, intestine, bone, appendages, eyes, and portions of the tissue or organs.
41. The method of claim 38 , wherein the balanced salt solution comprises:
calcium chloride dihydrate in a concentration of about 0.14 g/L;
potassium chloride in a concentration of about 0.4 g/L;
potassium phosphate monobasic in a concentration of about 0.06 g/L;
magnesium chloride hexahydrate in a concentration of about 0.1 g/L;
magnesium sulfate heptahydrate in a concentration of about 0.1 g/L sodium chloride in a concentration of about 8 g/L;
sodium bicarbonate in a concentration of about 0.36 g/L; and
sodium phosphate dibasic heptahydrate in a concentration of about 0.03 g/L.
42. The method of claim 38 , wherein the organ and tissue preservation solution comprises the ascorbic acid in a concentration of about 25-1000 μM, the glutathione in a concentration of about 50-2000 μM, the L-arginine in a concentration of about 250-2000 μM, and the sugar in a concentration of about 5.55 mM.
43. The method claimed in claim 38 , wherein the sugar is glucose.
44. The method of claim 38 , wherein the first precursor solution comprises the sugar.
45. The method of claim 38 , wherein the second precursor solution comprises the sugar.
46. A method of preserving living tissue, comprising:
combining a first precursor aqueous solution with a second precursor aqueous solution to form an organ and tissue preservation solution; and
contacting the living tissue with the organ and tissue preservation solution;
wherein the first precursor aqueous solution comprises a balanced salt solution, has a pH of about 7.4 to 8.0, and does not include reduced glutathione, L-Arginine or ascorbic acid,
wherein the second precursor aqueous solution comprises water, reduced glutathione, ascorbic acid, L-Arginine, and optionally, cysteinylglycine, at a pH of about 3.0 to 4.0,
wherein the organ and tissue preservation solution has a pH of about 7.3, and
wherein one of the first and second precursor aqueous solutions comprises a sugar.
47. The method of claim 46 , wherein the sugar is glucose.
48. The method of claim 46 , wherein the first precursor solution comprises the sugar.
49. The method of claim 46 , wherein the second precursor solution comprises the sugar.
50. The method of claim 46 , wherein the second precursor aqueous solution comprises cysteinylglycine.
51. The method of claim 46 , wherein the organ and tissue preservation solution comprises the ascorbic acid in a concentration of about 25-1000 μM, the glutathione in a concentration of about 50-2000 μM, the L-arginine in a concentration of about 250-2000 μM, and the sugar in a concentration of about 5.55 mM.
52. The method of claim 46 , wherein the balanced salt solution comprises:
calcium chloride dihydrate in a concentration of about 0.14 g/L;
potassium chloride in a concentration of about 0.4 g/L;
potassium phosphate monobasic in a concentration of about 0.06 g/L;
magnesium chloride hexahydrate in a concentration of about 0.1 g/L;
magnesium sulfate heptahydrate in a concentration of about 0.1 g/L
sodium chloride in a concentration of about 8 g/L;
sodium bicarbonate in a concentration of about 0.36 g/L; and
sodium phosphate dibasic heptahydrate in a concentration of about 0.03 g/L.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/684,495 US20220232822A1 (en) | 2013-11-22 | 2022-03-02 | Solutions for increasing the stability and shelf life of an organ and tissue preservation solution |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361963093P | 2013-11-22 | 2013-11-22 | |
PCT/US2014/066054 WO2015077199A1 (en) | 2013-11-22 | 2014-11-18 | Solutons for increasing the stability and shelf life of an organ tissue preservation solution |
US201614906582A | 2016-01-21 | 2016-01-21 | |
US17/684,495 US20220232822A1 (en) | 2013-11-22 | 2022-03-02 | Solutions for increasing the stability and shelf life of an organ and tissue preservation solution |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2014/066054 Division WO2015077199A1 (en) | 2013-11-22 | 2014-11-18 | Solutons for increasing the stability and shelf life of an organ tissue preservation solution |
US14/906,582 Division US11291201B2 (en) | 2013-11-22 | 2014-11-18 | Solutions for increasing the stability and shelf life of an organ and tissue preservation solution |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220232822A1 true US20220232822A1 (en) | 2022-07-28 |
Family
ID=52023642
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/906,582 Active 2036-08-05 US11291201B2 (en) | 2013-11-22 | 2014-11-18 | Solutions for increasing the stability and shelf life of an organ and tissue preservation solution |
US17/684,495 Pending US20220232822A1 (en) | 2013-11-22 | 2022-03-02 | Solutions for increasing the stability and shelf life of an organ and tissue preservation solution |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/906,582 Active 2036-08-05 US11291201B2 (en) | 2013-11-22 | 2014-11-18 | Solutions for increasing the stability and shelf life of an organ and tissue preservation solution |
Country Status (24)
Country | Link |
---|---|
US (2) | US11291201B2 (en) |
EP (1) | EP3027016B1 (en) |
JP (1) | JP2016537333A (en) |
KR (2) | KR102428676B1 (en) |
CN (1) | CN105916374B (en) |
AR (1) | AR098508A1 (en) |
AU (1) | AU2014353199B2 (en) |
BR (1) | BR112016006512B1 (en) |
CA (1) | CA2923441C (en) |
CL (1) | CL2016001003A1 (en) |
CR (1) | CR20160188A (en) |
DK (1) | DK3027016T3 (en) |
EA (1) | EA201691066A1 (en) |
ES (1) | ES2744637T3 (en) |
HK (1) | HK1220081A1 (en) |
IL (1) | IL244834B (en) |
MX (1) | MX2016006651A (en) |
MY (1) | MY181282A (en) |
PE (1) | PE20160861A1 (en) |
PH (1) | PH12016500909A1 (en) |
SG (1) | SG10201709595WA (en) |
TW (1) | TW201605342A (en) |
WO (1) | WO2015077199A1 (en) |
ZA (1) | ZA202210899B (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015077199A1 (en) * | 2013-11-22 | 2015-05-28 | Somahlution, Llc | Solutons for increasing the stability and shelf life of an organ tissue preservation solution |
EP3531832A4 (en) * | 2016-10-25 | 2020-08-05 | Marquette University | Storage media and powder formulations for avulsed teeth and explanted tissues comprising fibroblasts |
WO2023201038A1 (en) | 2022-04-15 | 2023-10-19 | Marizyme, Inc. | Powder formulations and use thereof in medical and/or surgical procedures |
WO2023224887A1 (en) * | 2022-05-16 | 2023-11-23 | Marizyme, Inc. | Use of cytoprotectant formulations in cell or tissue transport and/or storage |
WO2024076634A1 (en) | 2022-10-04 | 2024-04-11 | Marizyme, Inc. | Kits and use thereof in surgical procedures for endoscopic harvesting of vessels |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4550022A (en) | 1981-10-05 | 1985-10-29 | Alcon Laboratories, Inc. | Tissue irrigating solution |
US4443432A (en) | 1981-10-05 | 1984-04-17 | Alcon Laboratories, Inc. | Ophthmalic irrigating solution |
US5409904A (en) | 1984-11-13 | 1995-04-25 | Alcon Laboratories, Inc. | Hyaluronic acid compositions and methods |
US4798824A (en) | 1985-10-03 | 1989-01-17 | Wisconsin Alumni Research Foundation | Perfusate for the preservation of organs |
US4879283A (en) | 1985-10-03 | 1989-11-07 | Wisconsin Alumni Research Foundation | Solution for the preservation of organs |
US4837021A (en) | 1986-12-31 | 1989-06-06 | Laboratoires P.O.S. | Two part tissue irrigating solution |
US5304724A (en) | 1988-09-09 | 1994-04-19 | Entravision, Inc. | Tissue irrigating solution |
US4938961A (en) | 1989-04-28 | 1990-07-03 | Geoffrey Collins | Organ preservation solution containing pokyethylene gycol and method of performing cardioplegia |
US5257985A (en) | 1989-12-04 | 1993-11-02 | Richard Puhl | Multi-chamber intravenous bag apparatus |
US5066578A (en) * | 1989-12-21 | 1991-11-19 | The Regents Of The University Of California | Long-term preservation of organs for transplantation |
WO1992008349A1 (en) | 1990-11-07 | 1992-05-29 | Baxter International Inc. | Blood platelet storage medium |
EP0509083B1 (en) * | 1990-11-07 | 1997-07-16 | Baxter International Inc. | Red blood cell storage solution |
US5498427A (en) | 1990-11-20 | 1996-03-12 | Pasteur Merieux Serums Et Vaccines | Solutions for the perfusion, preservation and reperfusion of organs |
JP3326177B2 (en) * | 1992-06-26 | 2002-09-17 | 鳥居薬品株式会社 | Organ preservation solution |
BE1007500A3 (en) | 1992-09-18 | 1995-07-18 | Pasteur Merieux Serums Vacc | Solution infusion, conservation and organ reperfusion. |
ITPD940054A1 (en) | 1994-03-23 | 1995-09-23 | Fidia Advanced Biopolymers Srl | SULPHATED POLYSACCHARIDES |
JP3623294B2 (en) | 1995-11-28 | 2005-02-23 | 株式会社新素材総合研究所 | Medical container containing electrolyte and method for producing the same |
US8409846B2 (en) * | 1997-09-23 | 2013-04-02 | The United States Of America As Represented By The Department Of Veteran Affairs | Compositions, methods and devices for maintaining an organ |
US6153582A (en) | 1998-11-05 | 2000-11-28 | Bausch & Lomb Surgical, Inc. | Defined serumfree medical solution for ophthalmology |
US7611830B2 (en) | 2000-04-10 | 2009-11-03 | The United States Of America As Represented By The Department Of Veteran's Affairs | Device to lavage a blood vessel |
US6569615B1 (en) | 2000-04-10 | 2003-05-27 | The United States Of America As Represented By The Department Of Veteran's Affairs | Composition and methods for tissue preservation |
SI21704A (en) | 2004-01-14 | 2005-08-31 | Lek Farmacevtska Druzba Dd | New crystal form of perindopril, procedure of its preparation, pharmaceutical preparations containing this form and their application in treatment of hypertensia |
US20060093765A1 (en) | 2004-10-29 | 2006-05-04 | Sealed Air Corporation (Us) | Multi-compartment pouch having a frangible seal |
US20060160062A1 (en) | 2005-01-14 | 2006-07-20 | Young Lindon H | Perfusion and/or preservation solution for organs |
US9078428B2 (en) | 2005-06-28 | 2015-07-14 | Transmedics, Inc. | Systems, methods, compositions and solutions for perfusing an organ |
US7575856B2 (en) | 2005-10-28 | 2009-08-18 | The United States Of America As Represented By The Department Of Veterans Affairs | Compositions and methods for the evaluation and resuscitation of cadaveric hearts for transplant |
IL301141A (en) * | 2006-04-19 | 2023-05-01 | Transmedics Inc | Systems and methods for ex vivo organ care |
EP2543249B1 (en) | 2007-02-17 | 2018-05-23 | President and Fellows of Harvard College | Compositions and method for tissue preservation |
US20090035240A1 (en) * | 2007-07-31 | 2009-02-05 | Maes Daniel H | Aqueous Based Cosmetic Compositions Containing Resveratrol Derivatives And An Aqueous Phase Structuring Agent |
WO2009099132A1 (en) * | 2008-02-05 | 2009-08-13 | Kyowa Hakko Bio Co., Ltd. | Method for improving storage stability of glutathione |
BRPI0908181A2 (en) * | 2008-02-15 | 2015-08-18 | Harvard College | Cardioplegia solution for cardiac surgery |
US8608922B2 (en) | 2008-11-07 | 2013-12-17 | The University Of Connecticut | Biosensor for continuous monitoring of metabolites and proteins and methods of manufacture thereof |
WO2010054495A2 (en) | 2008-11-14 | 2010-05-20 | Profimed S.R.O. | Non-aqueous colloidal formulation |
US8288084B2 (en) | 2009-07-12 | 2012-10-16 | Revive Organtech, Inc. | Composition and method for flushing and cold/cryo preserving organs, tissues, and cells |
WO2011026498A1 (en) * | 2009-09-01 | 2011-03-10 | Medovent Gmbh | Chitosan tissue dressing |
FR2963965B1 (en) | 2010-08-20 | 2013-02-15 | Vallourec Mannesmann Oil & Gas | METHOD AND DEVICE FOR CONTROLLING A TUBULAR JOINT THREAD USED IN THE PETROLEUM INDUSTRY |
CN104981151A (en) * | 2012-12-31 | 2015-10-14 | 索玛解有限公司 | Organ and tissue preservation formulations with increased stability and shelf life |
WO2014109083A1 (en) * | 2013-01-09 | 2014-07-17 | 三菱マテリアル株式会社 | Copper alloy for electronic or electrical device, copper alloy thin sheet for electronic or electrical device, process for manufacturing copper alloy for electronic or electrical device, conductive component for electronic or electrical device, and terminal |
JP2016516830A (en) | 2013-04-24 | 2016-06-09 | ソマールション・エルエルシー | Preservation solution for organs and tissues with increased oxygen content, improved stability, and longer shelf life |
CN105407716A (en) * | 2013-04-29 | 2016-03-16 | 索玛解有限公司 | Formulations containing poly (0-2-hydroxyethyl) starch for increasing the oxygen-content, stability and shelf life of an organ and tissue preservation solution |
WO2015077199A1 (en) * | 2013-11-22 | 2015-05-28 | Somahlution, Llc | Solutons for increasing the stability and shelf life of an organ tissue preservation solution |
-
2014
- 2014-11-18 WO PCT/US2014/066054 patent/WO2015077199A1/en active Application Filing
- 2014-11-18 DK DK14812052.0T patent/DK3027016T3/en active
- 2014-11-18 US US14/906,582 patent/US11291201B2/en active Active
- 2014-11-18 EA EA201691066A patent/EA201691066A1/en unknown
- 2014-11-18 ES ES14812052T patent/ES2744637T3/en active Active
- 2014-11-18 MY MYPI2016701801A patent/MY181282A/en unknown
- 2014-11-18 CN CN201480061943.3A patent/CN105916374B/en active Active
- 2014-11-18 AU AU2014353199A patent/AU2014353199B2/en active Active
- 2014-11-18 KR KR1020167015581A patent/KR102428676B1/en active IP Right Grant
- 2014-11-18 BR BR112016006512-3A patent/BR112016006512B1/en active IP Right Grant
- 2014-11-18 SG SG10201709595WA patent/SG10201709595WA/en unknown
- 2014-11-18 JP JP2016525916A patent/JP2016537333A/en active Pending
- 2014-11-18 MX MX2016006651A patent/MX2016006651A/en unknown
- 2014-11-18 EP EP14812052.0A patent/EP3027016B1/en active Active
- 2014-11-18 CA CA2923441A patent/CA2923441C/en active Active
- 2014-11-18 KR KR1020227026130A patent/KR102570322B1/en active IP Right Grant
- 2014-11-18 PE PE2016000488A patent/PE20160861A1/en not_active Application Discontinuation
- 2014-11-21 AR ARP140104385A patent/AR098508A1/en active IP Right Grant
- 2014-11-21 TW TW103140510A patent/TW201605342A/en unknown
-
2016
- 2016-03-30 IL IL244834A patent/IL244834B/en active IP Right Grant
- 2016-04-22 CR CR20160188A patent/CR20160188A/en unknown
- 2016-04-27 CL CL2016001003A patent/CL2016001003A1/en unknown
- 2016-05-17 PH PH12016500909A patent/PH12016500909A1/en unknown
- 2016-07-13 HK HK16108205.6A patent/HK1220081A1/en unknown
-
2022
- 2022-03-02 US US17/684,495 patent/US20220232822A1/en active Pending
- 2022-10-04 ZA ZA2022/10899A patent/ZA202210899B/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220232822A1 (en) | Solutions for increasing the stability and shelf life of an organ and tissue preservation solution | |
EP2938186B1 (en) | Organ and tissue preservation formulations with increased stability and shelf life | |
CA3047360A1 (en) | Organ preservation and/or perfusion solutions | |
US20160088832A1 (en) | Formulations containing poly (0-2 hydroxyethyl) starch for increasing the oxygen-content, stability and shelf life of an organ and tissue preservation solution | |
TW201446964A (en) | Organ and tissue preservation solutions having increased oxygen-content, stability and shelf life | |
OA17766A (en) | Solutons for increasing the stability and shelf life of an organ tissue preservation solution | |
WO2023201038A1 (en) | Powder formulations and use thereof in medical and/or surgical procedures | |
TWI524843B (en) | Solution for preserving vascular conduits | |
TWI540961B (en) | Organ and tissue preservation formulations with increased stability and shelf life | |
OA17544A (en) | Solution for preserving vascular conduits. | |
AU2013370276A1 (en) | Solution for preserving vascular conduits |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MARIZYME, INC., FLORIDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SOMAHLUTION, LLC;REEL/FRAME:059144/0840 Effective date: 20201218 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |